Floatz logo

Bexarotene

Acute Myeloid Leukemia

Abramson Cancer Center at Penn MedicineSmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
59/ 100

Competitive context

374 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Shen yang
Phase 4BB
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
Gemtuzumab Ozogamicin
German Cancer Research Center
Phase 3BB
Azacitidine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 4BB

View all 50 →

Same molecule, other indications

Bexarotene is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
primary cutaneous anaplastic large cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
mycosis fungoidesDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →